Schering AG Ventavis CPMP opinion
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG's pulmonary hypertension agent Ventavis (iloprost) receives a positive opinion May 22 from EMEA's Committee for Proprietary Medicinal Products. Schering AG's U.S. subsidiary Berlex says it is evaluating the European Ventavis data and the implications for a U.S. submissio